Clinical aspects of Huntington’s disease

Current Topics in Behavioral Neurosciences

Volumn 22, Issue , 2014, Pages 3-31

  Ghosh, Rhia ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chorea; Genetics; Huntington s disease; Management; Natural history; Symptoms

Indexed keywords

ARIPIPRAZOLE; BACLOFEN; BOTULINUM TOXIN; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; ETIRACETAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LEVODOPA; MIRTAZAPINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TETRABENAZINE; TIZANIDINE; VALPROIC ACID; VENLAFAXINE;

ARTICLE; COGNITION; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISTRESS SYNDROME; GENE MUTATION; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SUICIDE; GENETICS; HUNTINGTON DISEASE; PATHOPHYSIOLOGY;

HUMANS; HUNTINGTON DISEASE;

EID: 84941144186     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2013_238     Document Type: Article

References (68)

1. Almqvist EW, Elterman DS, MacLeod PM et al (2001) High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 60(3):198-205
2. Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4(4):398-403
3. Aylward EH, Sparks BF, Field KM et al (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63(1):66-72
4. Ballard C, Howard R (2006) Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7(6):492-500
5. Barbeau A (1970) Parental ascent in the juvenile form of Huntington's chorea. Lancet 2(7679):937
6. Biglan KM, Zhang Y, Long JD et al (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci. doi:10.3389/fnagi.2013.00012
7. Björkqvist M, Wild EJ, Thiele J et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205(8):1869-1877
8. Bonelli RM, Hofmann P (2007) A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 8(2):141-153
9. Craufurd D, Snowden J (2002) Neuropsychological and neuropsychiatric aspects of Huntington's disease. In: Bates GP, Harper P, Jones L (eds) Huntington's disease, 3rd edn. Oxford University Press, Oxford, pp 62-94
10. Craufurd D, Tyler A (1992) Predictive testing for Huntington's disease: protocol of the UK Huntington's Prediction Consortium. J Med Genet 29(12):915-918
11. Evans SJ, Douglas I, Rawlins MD et al (2013) Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2012-304636
12. Goizet C, Lesca G, Dürr A et al (2002) Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias. Neurology 59(9):1330-1336
13. Guay DR (2010) Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 8(4):331-373
14. Gusella JF, Wexler NS, Conneally PM et al (1983) A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306(5940):234-238
15. Harper P (2002) The epidemiology of Huntington's disease. In: Bates GP, Harper P, Jones L (eds) Huntington's disease, 3rd edn. Oxford University Press, Oxford, pp 3-27
16. Harper PS, Lim C, Craufurd D (2000) Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. J Med Genet 37(8):567-571
17. Harrington DL, Smith MM, Zhang Y et al (2012) Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 83(6):612-619
18. Huntington G (1872) On chorea. Med Surg Report: Weekly J 26(15):317-321
19. Huntington Study Group (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136-142
20. Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66(3):366-372 International Huntington Association (IHA) and the World Federation of Neurology (WFN)
21. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea (1994) Neurology Guidelines for the molecular genetics predictive test in Huntington's disease. 44(8):1533-6
22. Killoran A, Biglan KM, Jankovic J et al (2013) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 80(22):2022-2027
23. Kirkwood SC, Siemers E, Stout JC et al (1999) Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol 56(5):563-568
24. Kremer B (2002) Clinical Neurology of Huntington's disease. In: Bates GP, Harper P, Jones L (eds) Huntington's disease, 3rd edn. Oxford University Press, Oxford, pp 28-53
25. Kremer B, Almqvist E, Theilmann J et al (1995) Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet 57(2):343-350
26. Langbehn DR, Brinkman RR, Falush D et al (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65(4):267-277
27. Langbehn DR, Hayden MR, Paulsen JS et al (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B(2):397-408
28. Lanska DJ, Lanska MJ, Lavine L et al (1988) Conditions associated with Huntington's disease at death. A case-control study. Arch Neurol 45(8):878-880
29. Lipe H, Schultz A, Bird TD (1993) Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. Am J Med Genet 48(4):231-233
30. Loy CT, McCusker EA (2013) Is a motor criterion essential for the diagnosis of clinical huntington disease? PLoS Curr. doi:10.1371/currents.hd.f4c66bd51e8db11f55e1701af937a419
31. Mason SL, Barker RA (2009) Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs 14(2):273-297
32. Myers RH, Sax DS, Koroshetz WJ et al (1991) Factors associated with slow progression in Huntington's disease. Arch Neurol 48(8):800-804
33. Novak MJ, Tabrizi SJ (2010) Huntington's disease. BMJ 340:c3109
34. Orth M, Handley OJ, Schwenke C et al (2010) Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr. doi:10.1371/currents.RRN1184
35. Orth M, Handley OJ, Schwenke C et al (2011) Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry 82(12):1409-1412
36. Paulsen JS, Ready RE, Hamilton JM et al (2001a) Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 71(3):310-314
37. Paulsen JS, Zhao H, Stout JC et al (2001b) Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57(4):658-662
38. Paulsen JS, Nehl C, Hoth KF et al (2005) Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci 17(4):496-502
39. Paulsen JS, Hoth KF, Nehl C et al (2005b) Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 162(4):725-731
40. Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874-880
41. Penney JB, Young AB, Shoulson I et al (1990) Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5(2):93-99
42. Rawlins M (2010) Huntington's disease out of the closet? Lancet 376(9750):1372-1373
43. Roos RA (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5(1):40
44. Rosenblatt A, Leroi I (2000) Neuropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics 41(1):24-30
45. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83-98
46. Rothlind JC, Bylsma FW, Peyser C et al (1993) Cognitive and motor correlates of everyday functioning in early Huntington's disease. J Nerv Ment Dis 181(3):194-199
47. Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59(1):16-22
48. Shoulson I, Chase TN (1975) Huntington's disease. Annu Rev Med 26:419-436
49. Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29(1):1-3
50. Siemers E, Foroud T, Bill DJ et al (1996) Motor changes in presymptomatic Huntington disease gene carriers. Arch Neurol 53(6):487-492
51. Siesling S, Vegter-van de Vlis M, Losekoot M et al (2000) Family history and DNA analysis in patients with suspected Huntington's disease. J Neurol Neurosurg Psychiatry 69(1):54-59
52. Snell RG, MacMillan JC, Cheadle JP et al (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4(4):393-397
53. Snowden JS, Craufurd D, Thompson J et al (2002) Psychomotor, executive, and memory function in preclinical Huntington's disease. J Clin Exp Neuropsychol 24(2):133-145
54. Tabrizi SJ, Langbehn DR, Leavitt BR et al (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791-801
55. Tabrizi SJ, Scahill RI, Durr A et al (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10(1):31-42
56. Tabrizi SJ, Reilmann R, Roos RA et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11(1):42-53
57. Tabrizi SJ, Scahill RI, Owen G et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12(7):637-649
58. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-983
59. van der Burg JM, Björkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 8(8):765-774
60. van der Steenstraten IM, Tibben A, Roos RA et al (1994) Predictive testing for Huntington disease: nonparticipants compared with participants in the Dutch program. Am J Hum Genet 55(4):618-625
61. van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 19(4):441-448
62. Videnovic A, Leurgans S, Fan W et al (2009) Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord 15(6):471-474
63. Went L (1990) Ethical issues policy statement on Huntington's disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology. J Med Genet 27(1):34-38
64. Wexler A (2010) Stigma, history, and Huntington's disease. Lancet 376(9734):18-19
65. Wexler NS, Lorimer J, Porter J et al (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 101(10):3498-3503
66. Wild EJ, Tabrizi SJ (2007) The differential diagnosis of chorea. Pract Neurol 7(6):360-373
67. Wild EJ, Mudanohwo EE, Sweeney MG et al (2008) Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 23(5):716-720
68. Zühlke C, Riess O, Bockel B et al (1993) Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Hum Mol Genet 2(12):2063-2067